Barclays analysts say upcoming global tariffs on pharmaceutical goods, expected to be imposed soon by President Donald Trump, will have varying impacts across the MedTech space. In a new report, the firm outlined which companies appear most and least exposed to the potential trade changes.
Among large-cap firms, Abbott (NYSE:ABT), Baxter (NYSE:BAX), Edwards Lifesciences (NYSE:EW), and Intuitive Surgical (NASDAQ:ISRG) all rated Overweight are expected to be among the least affected. Zimmer Biomet (NYSE:ZBH), rated Underweight, is also seen as having limited exposure.
In the small- and mid-cap group, Barclays highlighted Globus Medical (NYSE:GMED), Alphatec (NASDAQ:ATEC), and Tandem Diabetes Care (NASDAQ:TNDM) as relatively insulated from tariff risk, citing limited reliance on overseas manufacturing for U.S.-bound products.
On the other hand, companies more exposed include Medtronic (NYSE:MDT), Johnson & Johnson (NYSE:JNJ), and BD (NYSE:BDX) all rated Overweight along with Insulet (NASDAQ:PODD), InMode (NASDAQ:INMD), and Bausch + Lomb (NYSE:BLCO), which are rated Equal-Weight. These firms are more reliant on global production chains, potentially amplifying the impact of future trade restrictions.
Barclays suggests that tariff exposure could become a differentiating factor in the sector, as the policy takes shape.
This article first appeared on GuruFocus.免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。